BiotechTube
Home/Regel Therapeutics/Kate Allaway, Ph.D.
KA

Kate Allaway, Ph.D.

VP of Research

Regel Therapeutics

Therapeutic Areas

NeurologyGenetic Disorders

Regel Therapeutics Pipeline

DrugIndicationPhase
RT101Dravet SyndromePreclinical
RT102SCN2A HaploinsufficiencyPreclinical

Leadership Team at Regel Therapeutics

SJ
Stephen J. Farr, Ph.D.
CEO & Chairman of the Board
JD
Jordane Dimidschstein, Ph.D.
President, COO & Board Member
View full Regel Therapeutics profile